Pfizer Hopes for Second Time Lucky in Anti-inflammatory Drugs Collaboration
By Business Review Editor
Pharma Deals Review: Vol 2005 Issue 66 (Table of Contents)
Published: 5 Dec-2005
DOI: 10.3833/pdr.v2005.i66.589 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Incyte signed a major deal with Pfizer to develop, manufacture and market the oral chemokine receptor CCR2 antagonists...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS